310 related articles for article (PubMed ID: 22480363)
1. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.
Yoshida N; Doisaki S; Kojima S
Paediatr Drugs; 2012 Jun; 14(3):157-63. PubMed ID: 22480363
[TBL] [Abstract][Full Text] [Related]
2. [Juvenile myelomonocytic leukemias].
Lachenaud J; Strullu M; Baruchel A; Cavé H
Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
[TBL] [Abstract][Full Text] [Related]
3. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
Sakashita K
Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and treatment of juvenile myelomonocytic leukemia.
Sakashita K; Matsuda K; Koike K
Pediatr Int; 2016 Aug; 58(8):681-90. PubMed ID: 27322988
[TBL] [Abstract][Full Text] [Related]
5. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S
Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?
De Vos N; Hofmans M; Lammens T; De Wilde B; Van Roy N; De Moerloose B
Pediatr Blood Cancer; 2022 Nov; 69(11):e29930. PubMed ID: 36094370
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.
Koike K; Matsuda K
Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786
[TBL] [Abstract][Full Text] [Related]
8. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
Niemeyer CM; Flotho C
Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
[TBL] [Abstract][Full Text] [Related]
9. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience.
Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330
[TBL] [Abstract][Full Text] [Related]
10. Quantification of granulocyte-macrophage colony-stimulating factor hypersensitivity in juvenile myelomonocytic leukemia by 3H-thymidine assay.
Tanaka M; Takahashi Y; Xu Y; Yoshida N; Yoshimi A; Villalobos IB; Hama A; Nishio N; Hidaka H; Wang Y; Yagasaki H; Kojima S
Leuk Res; 2008 Jul; 32(7):1036-42. PubMed ID: 18164384
[TBL] [Abstract][Full Text] [Related]
11. Juvenile myelomonocytic leukemia.
Proytcheva M
Semin Diagn Pathol; 2011 Nov; 28(4):298-303. PubMed ID: 22195407
[TBL] [Abstract][Full Text] [Related]
12. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C
Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.
Bunda S; Kang MW; Sybingco SS; Weng J; Favre H; Shin DH; Irwin MS; Loh ML; Ohh M
Cancer Res; 2013 Apr; 73(8):2540-50. PubMed ID: 23400592
[TBL] [Abstract][Full Text] [Related]
14. In vitro expansion of CD34(+)CD38(-) cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia.
Sakashita K; Kato I; Daifu T; Saida S; Hiramatsu H; Nishinaka Y; Ebihara Y; Ma F; Matsuda K; Saito S; Hirabayashi K; Kurata T; Uyen LT; Nakazawa Y; Tsuji K; Heike T; Nakahata T; Koike K
Leukemia; 2015 Mar; 29(3):606-14. PubMed ID: 25102944
[TBL] [Abstract][Full Text] [Related]
15. Juvenile myelomonocytic leukemia.
Satwani P; Kahn J; Dvorak CC
Pediatr Clin North Am; 2015 Feb; 62(1):95-106. PubMed ID: 25435114
[TBL] [Abstract][Full Text] [Related]
16. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
Locatelli F; Algeri M; Merli P; Strocchio L
Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
[TBL] [Abstract][Full Text] [Related]
17. After 95 years, it's time to eRASe JMML.
Meynier S; Rieux-Laucat F
Blood Rev; 2020 Sep; 43():100652. PubMed ID: 31980238
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
Kim HS; Lee JW; Kang D; Yu H; Kim Y; Kang H; Lee JM; Ahn A; Cho B; Kim S; Chung NG; Kim Y; Kim M
Br J Haematol; 2021 Dec; 195(5):748-756. PubMed ID: 34590720
[TBL] [Abstract][Full Text] [Related]
19. Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features.
Tüfekçi Ö; Ören H; Demir Yenigürbüz F; Gözmen S; Karapınar TH; İrken G
Turk J Haematol; 2015 Jun; 32(2):175-9. PubMed ID: 26316488
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment.
Leoncini PP; Bertaina A; Papaioannou D; Flotho C; Masetti R; Bresolin S; Menna G; Santoro N; Zecca M; Basso G; Nigita G; Veneziano D; Pagotto S; D'Ovidio K; Rota R; Dorrance A; Croce CM; Niemeyer C; Locatelli F; Garzon R
Oncotarget; 2016 Aug; 7(34):55395-55408. PubMed ID: 27447965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
